Short-term inhibition of parathyroid hormone secretion by a calcium- receptor agonist in patients with primary hyperparathyroidism

New England Journal of Medicine

Volumn 337, Issue 21, 1997, Pages 1506-1510

  Silverberg, Shonni J ^a   Bone III, Henry G ^b   Marriott, Thomas B ^c   Locker, Flore G ^a   Thys Jacobs, Susan ^a   Dziem, Greg ^d   Kaatz, Scott ^b   Sanguinetti, Elizabeth L ^c   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

^b HENRY FORD HOSPITAL   (United States)

^c NPS Pharmaceutical Inc   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; PARATHYROID HORMONE; R 568; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL ARTICLE; FEMALE; HORMONE INHIBITION; HUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL;

AGED; ANILINE COMPOUNDS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPARATHYROIDISM; MIDDLE AGED; PARATHYROID HORMONE;

EID: 0030667380     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199711203372104     Document Type: Article

References (30)

1. Silverberg SJ, Fitzpatrick LA, Bilezikian JP. Primary hyperparathyroidism. In: Becker KL, Bilezikian JP, Bremner WJ, eds. Principles and practice of endocrinology and metabolism. 2nd ed. Philadelphia: J.B. Lippincott, 1995:512-9.
2. Kleerekoper M. Clinical course of primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroids: basic and clinical concepts. New York: Raven Press, 1994:471-84.
3. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:2036-40.
4. National Institutes of Health. Consensus development conference statement on primary hyperparathyroidism. J Bone Miner Res 1991;6:Suppl: S9-S13.
5. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988;67:1294-8.
6. Parfitt AM, Rao DS, Kleerekoper M. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res 1991;6:Suppl 2:S97-S101.
7. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995;80:723-8.
8. Medical management of primary hyperparathyroidism. Lancet 1984;2: 727-8.
9. Nemeth EF, Scarpa A. Rapid mobilization of cellular Ca2+ in bovine parathyroid cells evoked by extracellular divalent cations: evidence for a cell surface calcium receptor. J Biol Chem 1987;262:5188-96.
10. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575-80.
11. Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cellsurface receptors. N Engl J Med 1995;333:234-40.
12. Brown EM, Katz C, Butters R, Kifor O. Polyarginine, polylysine, and protamine mimic the effects of high extracellular calcium concentrations on dispersed bovine parathyroid cells. J Bone Miner Res 1991;6:1217-25.
13. Nemeth EM. Calcium receptors as novel drug targets. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. New York: Academic Press, 1996:1019-36.
14. Fox J, Hadfield S, Petty BA, Nemeth EF. A first generation calcimimetic compound (NPS R-568) that acts on the parathyroid cell calcium receptor: a novel therapeutic approach for hyperparathyroidism. J Bone Miner Res 1993;8:Suppl 1:S181. abstract.
15. Steffey ME, Fox J, Van Wagenen BC, DelMar EG, Balandrin MF, Nemeth EF. Calcimimetics: structurally and mechanistically novel compounds that inhibit hormone secretion from parathyroid cells. J Bone Miner Res 1993;8:Suppl 1:S175. abstract.
16. Clark OH, Wilkes W, Siperstein AE, Duh QY. Diagnosis and management of asymptomatic hyperparathyroidism: safety, efficacy, and deficiencies in our knowledge. J Bone Miner Res 1991;6:Suppl 2:S135-S142.
17. Norton JA, Brennan MF, Wells SA Jr. Surgical management of hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroids: basic and clinical concepts. New York: Raven Press, 1994:531-51.
18. Stock JL, Marcus R. Medical management of primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroids: basic and clinical concepts. New York: Raven Press, 1994:519-29.
19. Albright F, Bauer W, Claflin D, Cockrill JR. Studies in parathyroid physiology. III. The effect of phosphate ingestion in clinical hyperparathyroidism. J Clin Invest 1932;11:411-35.
20. Purnell DC, Scholz DA, Smith LM, et al. Treatment of primary hyperparathyroidism. Am J Med 1974;56:800-9.
21. Broadus AE, Magee JS, Mallette LE, et al. A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism. J Clin Endocrinol Metab 1983;56:953-61.
22. Vernava AM III, O'Neal LW, Palermo V. Lethal hyperparathyroid crisis: hazards of phosphate administration. Surgery 1987;102:941-8.
23. Marcus R, Madvig P, Crim M, Pont A, Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984;100:633-40.
24. Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986;314:1481-5.
25. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized, controlled trial. Ann Intern Med 1996;125:360-8.
26. Shane E, Baquiran DC, Bilezikian JP. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 1981;95:23-7.
27. Licata AA, O'Hanlon E. Treatment of hyperparathyroidism with etidronate disodium. JAMA 1983;249:2063-4.
28. Douglas DL, Kanis JA, Paterson AD, et al. Drug treatment of primary hyperparathyroidism: use of clodronate disodium. BMJ 1983;286: 587-90.
29. Schmidli RS, Wilson I, Espiner EA, Richards AM, Donald RA. Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status. Clin Endocrinol (Oxf) 1990;32:293-300.
30. Heath H III, Sanguinetti EL, Oglesby S, Marriott TB. Inhibition of human parathyroid hormone secretion in vivo by NPS R-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor. Bone 1995;16:Suppl:85S. abstract.